This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gotto, A. M. Search for Related Content PubMed Articles by Gotto, A. M., Jr

(Circulation. 2004;109:III-1.)
© 2004 American Heart Association, Inc.

Atherosclerosis: Evolving Vascular Biology and Clinical Implications

Introduction

Antonio M. Gotto, Jr, MD, DPhil

Weill Medical College of Cornell University, New York, NY

An extract of the first 250 words of the full text is provided, because this article has no abstract.

This supplement to Circulation has been developed by the International Lipid Information Bureau (ILIB), a group of leading investigators and clinicians in the field of dyslipidemia and atherosclerotic disease. The ILIB is an educational effort intended to supplement the work of governmental and nonprofit organizations in disseminating up-to-date scientific and clinical information, thereby helping to reduce the international burden of cardiovascular disease. ILIB activities serve as a resource for physicians and other medical professionals, the public, and the media. Supported by unrestricted educational grants from Pfizer Inc, the ILIB is an intellectually independent body committed to fair balance in all of its activities.

The current supplement, entitled Atherosclerosis: Evolving Vascular Biology and Clinical Implications, provides state-of-the-art reviews of topics related to the pathophysiology of atherosclerosis, while highlighting the clinical implications of recent and ongoing research efforts in vascular biology. Specific topics and authors are as follows:

"Atherogenic Lipoprotein Particles in Atherosclerosis," by Drs Rafael Carmena, Patrick Duriez, and Jean-Charles Fruchart, goes beyond the traditional emphasis on low-density lipoprotein (LDL) cholesterol to describe the role of other lipid/lipoprotein subfractions in the initiation and progression of atherosclerosis. The importance of the heterogeneity of LDL particles is also discussed.

"HDL Cholesterol and Protective Factors in Atherosclerosis," by Drs Gerd Assmann and Antonio M. Gotto, Jr, explores the protective role of high-density lipoprotein (HDL) cholesterol and considers its potential as a target of pharmacological intervention.

In "New Risk Factors for Atherosclerosis and Patient Risk Assessment," Drs Jean-Charles Fruchart, Melchior C. Nierman, Eric S.G. . . . [Full Text of this Article]